Community Pharmacists Monitoring of Pulmonary Tuberculosis Outpatients (Preliminary Study)

Slides:

Advertisements

Similar presentations

EFFECTIVENESS OF DOTS THERAPY IN TUBERCULAR PATIENTS IN BANGALORE RURAL DISTRICT. Department of Pharmacy Practice, Visveswarapura Institute of Pharmaceutical.

Advertisements

DOTS/ DOTS PLUS IMPLEMENTATION AND INTEGRATION Vaira Leimane State Centre of Tuberculosis and Lung Diseases of Latvia Paris, October, 28.

PPM-DOTS in Cambodia Working with Private Pharmacies DOTS Expansion WG Meeting Paris 15 th October 2008 Dr. Mao Tan Eang Director National Center for TB.

Key elements to develop a national strategic plan for TB control Malgosia Grzemska Stop TB Department WHO, Geneva, Switzerland EURO/TBTEAM Regional Workshop.

Adherence Ensuring Better Patient Outcomes Lecture # 2 Ghadah Asaad Assiri,MSc May 2014.

Decentralisation as a Strategy to Address Major Challenges of DOTS Services: Experience of Kano State, Nigeria Mahmoud Nasir Mohammed 1, Tijjani Hussaini.

Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.

Inaugural Conference of the African Health Economics and Policy Association (AfHEA) Accra - Ghana, 10th - 12th March 2009 Patent medicines vendors a resource.

International Standards of Tuberculosis Care Implementation by Pulmonologists in Private Practice in Jakarta E. Burhan 1, M. A. Nawas 1, D. Kusumo Sutoyo.

Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital

Introduction Hypothesis Conclusions Specific Aims In-home Intervention Improves Outcomes of Tuberculosis Patients in Zimbabwe, Africa Olga Kishek, Tess.

Monitoring and Evaluation: A Review of Terms. Goals To provide better treatment for people with tuberculosis in Country X To achieve a treatment success.

Clinical Pharmacist Intervention in Cardiac Patients With Renal Impairment Elham Al-Shammari, B.Sc. Pharm. Hisham Abou-Auda, Ph. D. Meshal Al-Mutairi,

Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.

China TB Control Progress Report The ninth Technical Advisory Group and National TB Programme Managers meeting for TB control in the Western Pacific Region.

Revised National Tuberculosis Control Programme (RNTCP)

Progress and Plans for PPM in the Western Pacific Region Fifth PPM DOTS Subgroup Meeting Cairo, Egypt.

Outcomes among patients treated for tuberculosis in Limpopo Province, South Africa, Mmakgotso Pilane, Lazarus Kuonza, Eric Maimela.

Integrating Pharm.D. Education with University Pharmacies for Supporting Coverage of Diabetes and Hypertension Screening in Thai Communities Ploylearmsang.

TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.

Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,

Lung-2015 Baltimore, USA July , 2015 Suhaj A.

Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.

Tuberculosis control in Suriname Situational analysis.

Summary Pattern of Specific COX II Inhibitors Use Physician prescribed appropriate COX II use in high risk was 40.08% and inappropriate COX II use in low.

Bringing Hepatitis C Treatment into the Medical Home A Pilot Program for Drug Users Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission.

1 Identifying Contribution of Community-based DOTS in Treatment Outcome of TB Patients in Four Provinces of Afghanistan Qader, Ghulam MD, DPH, MPH Senior.

MODEL OF INFECTIOUS DISEASES AND OUTBREAKS IN VIETNAM MILITARY ( ) Sr.Col. Le Ngoc Anh, MD. PhD. Vietnam Military Medical Department.

Methadone Maintenance System Performance Measures – 2011/2012 Office of the Provincial Health Officer January 28, Dr. Eric Young, MD, MHSc, CCFP,

Introducing fixed dose combination tablets into DR CONGO using the Global TB Drug Facility.

Global Clinical Engineering Success Stories Maintenance of medical devices Name: Ledina Picari Affiliation: CED Collaborator Location: Tirana, Albania.

Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.

Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.

Perceptions of a pharmacist in an ambulatory care setting

Presented by: Katie Sindelar, Clinton Health Access Initiative

A Way out of Directly Observed Therapy (DOT): Community approaches to Self-Administered Treatment for Rifampicin Resistant Tuberculosis in Khayelitsha,

TB/ HIV CONTROL AND MANAGEMENT IN SOUTH AFRICA

Clinical Pharmacists' Recommendations in Critical Care Areas of an Egyptian Tertiary Care Hospital: Interventions Analysis and Effect on Direct Drug Cost.

of Patients with Acute Myocardial Infarction (AMI)

Universal Health Coverage Conference

Monitoring and Evaluation Frameworks

TB- HIV Collaborative activities in Romania- may 2006 status

Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital

CTC Clinical Strategy and Cost Committee

NURSES ROLE IN THE CARE AND MANAGEMENT OF MDR-TB

Believed discrimination occurred because of their:

Daffodil International University (DIU), Dhaka Bangladesh

R Nagar 1, Debashish Kundu2, S Chandra2 , A Khanna1

Context Objectives Results Discussion and Recommendations Conclusion

MHEALTH to Improve Health: Effectiveness of a weekly text messaging intervention to improve ART adherence and HIV Viral Load: WelTel OAKTREE. M.C.M. Murray1,2,3,

PAEDIATRIC TUBERCULOSIS MAY STILL BE UNDER DIAGNOSED AND UNDER TREATED

Lecture 1 Introduction Kanar Fadhil Hidayat MSc. Pharmacy

اهمیت سل در چیست؟ حدود یک سوم جمعیت جهان(2 میلیارد نفر)با میکروب سل آلوده شده اند سالانه 9 میلیون نفر به سل فعال مبتلا می شوند هر ساله 1/5 تا 2 میلیون.

Background 1 § About 1/3 of world population infected with Tuberculosis (TB) § 25% of all avoidable deaths in developing countries due to TB.

2Public Health Unit. Komfo Anokye Teaching Hospital

Community Pharmacists Monitoring of Pulmonary Tuberculosis Outpatients (Preliminary Study)

Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002–11, and requirements.

TB epidemiological situation in Kyrgyzstan

Pharmaceutical care planning 2 Ola Ali Nassr

DOTS EXPANSION AND BEYOND DOTS World Health Organization

From TB control to integrated respiratory disease control

DOTS IMPACT TO TUBERCULOSIS IN LITHUANIA

TB epidemiology in Bulgaria

Lecture 1 Introduction Kanar Fadhil Hidayat MSc. Pharmacy

How will the NHS Long Term Plan work in our community?

Adults with Health Problems Who Have an Excellent Patient Experience Are Most Likely to Be Well-Informed About Their Prescription Medications Percent of.

Quality Improvement (A) (B) % Smokers Receiving Medication

33rd IUATLD World Conference on Lung Health

Monitoring and Evaluation: A Review of Terms

Best Practices in Building HIV Care Networks

Presentation transcript:

Community Pharmacists Monitoring of Pulmonary Tuberculosis Outpatients (Preliminary Study)

Authors Usasiri Srisakul, M.Sc. in Pharm (Clinical Pharmacy) Phayom Sookaneknun, PharmD Sunantha Osiri, Ph.D Institution: Faculty of Pharmacy and Health Sciences, Mahasarakham University, Thailand, 44150 Study funded by: Health Systems Research Institute (HSRI), Thailand

Introduction DOTS (Directly Observed Treatment, Short Course) for pulmonary tuberculosis (PulTB) is a major strategy in the National Tuberculosis Programme (NTP) following WHO global plan. Thailand ranked the 16th in 22 high-burden countries.

Objectives To compare clinical outcome between Community pharmacists monitoring patients Control patients receiving normal care

Method Quasi experimental study design Patients: Preliminary study: Pulmonary Tuberculosis (PulTB) without HIV co-infection DOT category 1 (2HRZE + 4HR) December 2002 – January 2004 Mahasarakham provincial hospital Preliminary study: December 2002 – October 2003 N = 54

PulTB with DOT category1 N=54 Completed intensive treatment phase 2nd month Volunteered Community pharmacists monitoring group N=27 Control group N=27 3rd – 5th month Clinical outcomes 6th month Figure 1 Research procedure

Method (cont.) Community Pharmacists monitoring group Control group Refill of DOTS medication (1-4 weekly follow up) Pharmaceutical care Control group Normal care from the hospital (1-3 monthly follow up) Clinical outcomes Cure rate Treatment success rate Default rate Failure rate

Results: Demographic data Treatment gr. Control gr. p-value N=27 Age (year) 54.15 + 15.31 51.22 + 16.00 0.495 Male (%) 16 (47.10%) 18 (52.90%) 0.573 Smear positive (%) 17 (63.00%) 12 (44.44%) 0.172 No significant differences in all demographic data betweent both groups.

Results: Clinical outcomes Treatment gr. Control gr. p-value N=27 Cure rate 94.12% (16) 66.67% (8 ) 0.054 Treatment Success rate 96.30% (26) 74.10% (20) 0.022* Default rate 3.7% (1) 22.22% (6) 0.043* Failure rate 0% (0) 0.313 * Significant differences

Results: Clinical outcomes 0.022* 0.054 0.043* 0.313 Figure 2 Clinical outcomes

Discussion Community pharmacist monitoring can improve treatment succes rate (WHO goal > 85%), decrease default and failure rate Show the community pharmacist involvement in DOTS multidisciplinary team In the future study should be expanded number of patients, community pharmacy setting and referral system

Conclusion Community pharmacist involvement in a DOTS multidisciplinary team improved clinical outcomes in pulmonary tuberculosis outpatients.

Thank you very much